Art Biktarvy denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for art biktarvy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Prior Authorization for Biktarvy — and What to Do

Blue Cross Blue Shield requires prior authorization (PA) for Biktarvy (bictegravir/tenofovir alafenamide/emtricitabine) as a cost-management and utilization-management tool. A "prior-auth-required" denial means the prescription was dispensed or submitted without a PA approval already on file. This is procedural, not clinical — but it becomes an access problem when the PA is denied or delayed.

If you received this denial because a PA was not obtained in advance, your prescriber can submit a retroactive PA request. If a PA was submitted and denied on clinical grounds, you have full appeal rights.

## The Federal Appeal Framework

• ACA §2719 External Review: If internal appeal fails, independent external review is available. Filing deadline is typically around 180 days from the denial — verify the exact date on your letter.
• ERISA §503 (employer-sponsored plans): Full-and-fair review right with written explanation of the specific plan provisions relied upon.
• Expedited / Urgent PA: If you need the medication urgently, request an expedited PA determination. For urgent situations, plans are typically required to respond within 72 hours or less.
• Continuity-of-care provisions: If you were previously covered for Biktarvy under a prior plan or prior coverage year, note this in your appeal — many plans have continuity-of-care protections.

## What to Gather

1. Completed PA request form — obtain BCBS's current PA request form for specialty HIV medications; have your prescriber complete it with full clinical justification. 2. Diagnosis and clinical documentation — chart notes confirming HIV-1 diagnosis, current treatment status, viral load and CD4 history (from chart), and treatment history. 3. Prior treatment documentation — records of previous antiretroviral regimens, outcomes, and rationale for current regimen selection. 4. Prescriber medical-necessity letter — should address each of the PA criteria listed in BCBS's coverage policy for Biktarvy. 5. BCBS's published PA criteria for Biktarvy — obtain these before your prescriber writes the letter so every criterion is addressed explicitly.

## Criteria-Mapping Structure

| BCBS Prior-Auth Criterion | Documentation That Satisfies It | |---|---| | [Paste each PA criterion from the plan's published policy] | [Chart note, lab, or prescriber statement that directly addresses it] |

## Next Steps

Have the prescriber's office submit the PA with the full clinical package proactively. Request peer-to-peer review with the plan's medical director at the same time as the PA submission. If the PA is denied, file a formal internal appeal immediately and invoke expedited review given the clinical importance of uninterrupted HIV therapy.